| 51 |
27044711 | A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | 2016 Jul |
2 |
| 52 |
27166836 | Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells. | 2016 Jul |
2 |
| 53 |
25304212 | A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. | 2015 Jan |
1 |
| 54 |
25527332 | The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. | 2015 Jan |
2 |
| 55 |
25686603 | Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. | 2015 Mar 5 |
1 |
| 56 |
25801024 | Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. | 2015 Mar 24 |
1 |
| 57 |
25894969 | Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. | 2015 |
6 |
| 58 |
26195136 | Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. | 2015 Sep 1 |
1 |
| 59 |
26458439 | [State-of-the-art management of CML in 2015 and future prospects]. | 2015 Oct |
2 |
| 60 |
26562217 | Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase. | 2015 Dec 10 |
1 |
| 61 |
24258348 | Ever-advancing chronic myeloid leukemia treatment. | 2014 Feb |
2 |
| 62 |
24297701 | BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. | 2014 Mar |
1 |
| 63 |
24408322 | Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. | 2014 Mar 6 |
1 |
| 64 |
24481648 | Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. | 2014 Apr |
1 |
| 65 |
24552773 | Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling. | 2014 May |
2 |
| 66 |
24756787 | Ponatinib: a third-generation inhibitor for the treatment of CML. | 2014 |
2 |
| 67 |
24768818 | Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. | 2014 Jun 26 |
1 |
| 68 |
25382104 | Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. | 2014 Nov 10 |
1 |
| 69 |
25465127 | Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. | 2014 Dec 2 |
1 |
| 70 |
25536607 | Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes. | 2014 Oct-Dec |
2 |
| 71 |
22781593 | Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. | 2013 Jan |
2 |
| 72 |
23223358 | BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. | 2013 Jan 17 |
1 |
| 73 |
23372106 | Treating chronic myeloid leukemia: improving management through understanding of the patient experience. | 2013 Feb |
1 |
| 74 |
23409026 | Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. | 2013 |
2 |
| 75 |
23576564 | Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. | 2013 Jun 1 |
2 |
| 76 |
23616953 | Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. | 2013 Apr |
1 |
| 77 |
23684619 | Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells. | 2013 Jun 7 |
2 |
| 78 |
23787070 | Bcr-Abl tyrosine kinase inhibitors- current status. | 2013 Jun 20 |
4 |
| 79 |
23888935 | Effects of food on the pharmacokinetics of ponatinib in healthy subjects. | 2013 Dec |
1 |
| 80 |
23986642 | Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. | 2013 |
2 |
| 81 |
24159169 | Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells. | 2013 Oct 24 |
1 |
| 82 |
24180494 | A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. | 2013 Nov 7 |
2 |
| 83 |
24236021 | Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. | 2013 |
5 |
| 84 |
22238366 | Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. | 2012 Mar |
2 |
| 85 |
22503441 | Structural approaches to obtain kinase selectivity. | 2012 May |
1 |
| 86 |
22519766 | Tyrosine kinase inhibitors in acute and chronic leukemias. | 2012 May |
1 |
| 87 |
22532521 | Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. | 2012 Sep |
1 |
| 88 |
22778153 | The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. | 2012 Sep |
5 |
| 89 |
22956142 | An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents. | 2012 |
2 |
| 90 |
23044928 | Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. | 2012 Nov |
1 |
| 91 |
23187745 | Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. | 2012 Oct |
1 |
| 92 |
23190221 | Ponatinib in refractory Philadelphia chromosome-positive leukemias. | 2012 Nov 29 |
3 |
| 93 |
23190395 | Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors. | 2012 Dec 19 |
1 |
| 94 |
23238683 | All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib. | 2012 Dec |
2 |
| 95 |
21098337 | Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. | 2011 Jan 15 |
1 |
| 96 |
21482694 | Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. | 2011 Jun |
2 |
| 97 |
21700550 | [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?]. | 2011 Jul |
1 |
| 98 |
19878872 | AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. | 2009 Nov 6 |
2 |